XML 24 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual) (USD $)
Share data in Millions, unless otherwise specified
 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended
Mar. 31, 2014
Observation
Sep. 24, 2012
Observation
Feb. 13, 2012
Observation
Feb. 10, 2012
Observation
Apr. 21, 2014
Feb. 25, 2014
Oct. 15, 2012
Mar. 05, 2012
May 31, 2014
Intangible_Asset
Investment
May 31, 2013
Investment
May 31, 2012
May 22, 2012
Jun. 30, 2012
Business Acquisition [Line Items]                          
Costs for quality call to action program                 $ 3,200,000ango_CostsForQualityCallToActionProgram        
Number of observations 3ango_NumberOfObservations 5ango_NumberOfObservations 6ango_NumberOfObservations 12ango_NumberOfObservations                  
Number of business days to provide response to FDA         15 days 15 days 15 days 15 days          
Short Term Investments Maturity Period                 less than three months        
Investments in auction rate securities that failed auctions                 1,809,000us-gaap_AvailableforsaleSecuritiesFailedAuctionValue 1,800,000us-gaap_AvailableforsaleSecuritiesFailedAuctionValue      
Number of investments                 2ango_NumberOfInvestmentsFailedAtAuction 2ango_NumberOfInvestmentsFailedAtAuction      
Number of Indefinite Lived Intangible Assets                 1ango_NumberOfIndefiniteLivedIntangibleAssets        
Restocking charge percentage                 20.00%ango_PercentageOfRestockingCharge        
Estimated net operating losses, prior to utilization                 13,000,000ango_StateNetOperatingLossExpectedToExpireBeforeUtilization        
Potential amount of undiscounted future contingent consideration                 78,100,000ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure        
Milestones associated with the contingent consideration                 56,400,000ango_NoncurrentPortionContingentMilestonePaymentsFairValueDisclosure        
Reflected in current portion of contingent consideration                 10,900,000ango_ContingentConsiderationAtRemeasurementDate        
Interest expense on derivative financial instruments                   61,000ango_DerivativeInstrumentInterestExpense      
Notional amount of interest rate swap agreement                 100,000,000us-gaap_DerivativeAssetNotionalAmount        
Fixed interest rate payments                         3.26%us-gaap_DerivativeSwaptionInterestRate
Stock-based compensation, options vested, percentage                 88.00%ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestPercentage        
Stock-based compensation, options forfeiture rate                 12.00%ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRate        
Dividend paid                 0us-gaap_PaymentsOfDividends        
Antidilutive securities excluded from computation of diluted earnings per share                 2.3us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 2.9us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 2.3us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount    
Clinical Devices, B.V. [Member] | Trademark-NAMIC [Member]                          
Business Acquisition [Line Items]                          
Acquired intangible asset                 3,600,000us-gaap_IndefinitelivedIntangibleAssetsAcquired
/ us-gaap_BusinessAcquisitionAxis
= ango_ClinicalDevicesB.V.Member
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= ango_TrademarkNamicMember		        
Navilyst [Member]                          
Business Acquisition [Line Items]                          
Weighted average useful life                       10 years  
Federal net operating losses, unutilized                 17,500,000ango_FederalNetOperatingLossesUnutilized
/ us-gaap_BusinessAcquisitionAxis
= ango_NavilystMember		        
Estimated net operating losses, prior to utilization                 13,000,000ango_StateNetOperatingLossExpectedToExpireBeforeUtilization
/ us-gaap_BusinessAcquisitionAxis
= ango_NavilystMember		        
Navilyst [Member] | Trademark-NAMIC [Member]                          
Business Acquisition [Line Items]                          
Acquired intangible asset                 28,600,000us-gaap_IndefinitelivedIntangibleAssetsAcquired
/ us-gaap_BusinessAcquisitionAxis
= ango_NavilystMember
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= ango_TrademarkNamicMember		     28,600,000us-gaap_IndefinitelivedIntangibleAssetsAcquired
/ us-gaap_BusinessAcquisitionAxis
= ango_NavilystMember
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= ango_TrademarkNamicMember		  
RITA [Member]                          
Business Acquisition [Line Items]                          
Federal net operating losses, unutilized                 15,800,000ango_FederalNetOperatingLossesUnutilized
/ us-gaap_BusinessAcquisitionAxis
= ango_RitaMember		        
Federal net operating losses, utilized                 7,100,000ango_FederalNetOperatingLossesExpired
/ us-gaap_BusinessAcquisitionAxis
= ango_RitaMember		        
Estimated net operating losses, prior to utilization                 $ 13,600,000ango_StateNetOperatingLossExpectedToExpireBeforeUtilization
/ us-gaap_BusinessAcquisitionAxis
= ango_RitaMember		        
Maximum [Member]                          
Business Acquisition [Line Items]                          
Accounts receivables period due                 90 days        
Weighted average useful life                 20 years        
Minimum [Member]                          
Business Acquisition [Line Items]                          
Accounts receivables period due                 30 days        
Weighted average useful life                 3 years        
Undamaged product expiration date                 12 months